PROKIDNEY CORP (PROK)

KYG7S53R1049 - Common Stock

2.32  -0.07 (-2.93%)

Full profile views are only available for registered users, you can see which data is available below.

Examples of complete profiles are available for MSFT and AAPL.

Registered users have access to more data. Please register or login for additional data.

PROKIDNEY CORP

NASDAQ:PROK (7/16/2024, 12:09:51 PM)

2.32

-0.07 (-2.93%)

Chartmill TA Rating
Chartmill Setup Rating
Sector
GICS SectorHealth Care
GICS IndustryBiotechnology
GICS SubIndustry
Chartmill FA Rating
Valuation
Growth
Profitability
Health
Dividend
Chartmill High Growth Momentum
EPS Q2Q%
Sales Q2Q%
CRS
6 Month83.85%
Overview
Earnings (Last)
Earnings (Next)
Ins Owners
Inst Owners
Market Cap656.84M
Shares
PEN/A
Fwd PEN/A
Dividend YieldN/A
Analysts
IPO
Stock Screener Links
Screen Image

Nasdaq Stock Screener

Find more stocks on Nasdaq

Screen Image

USA Stock Screener

Find more stocks on the USA

Screen Image

GICS Sector Stock Screener

Find competitors from the same sector on the USA

Screen Image

GICS Industry Stock Screener

Find competitors from the same industry on the USA

Screen Image

Technical Stock Screener

Find stocks with similar TA and Setup ratings on the USA

Screen Image

Fundamental Stock Screener

Find stocks with similar Fundamental rating on the USA

Screen Image

Best Technical Competitors Stock Screener

Find the competitors with the best technical ratings on the USA

Screen Image

Best Technical Setups Competitors Stock Screener

Find the competitors with the best technical and setup ratings on the USA

Screen Image

Best Fundamental Competitors Stock Screener

Find the competitors with the best fundamentals on the USA

Screen Image

Best Valuation Competitors Stock Screener

Find the competitors with the best valuation on the USA

Screen Image

Best Dividend Competitors Stock Screener

Find the competitors with the best dividend on the USA

Screen Image

Best Analyst Rating Competitors Stock Screener

Find the competitors with the best analyst ratings on the USA

PROK Daily chart

Company Profile

ProKidney Corp. is a clinical-stage biotechnology company, which engages in the development of proprietary cell therapy platform. The company is headquartered in Winston-Salem, North Carolina and currently employs 87 full-time employees. The company went IPO on 2021-06-30. The firm is focused on cell therapy platforms capable of treating multiple chronic kidney diseases (CKD) using a patient’s own cells isolated from the patient intended for treatment. The Company’s lead product candidate, Renal Autologous Cell Therapy (REACT), is designed to preserve kidney function in a CKD patient’s diseased kidneys. REACT is a product that includes autologous Selected Renal Cells (SRCs) prepared from a patient’s own (autologous) kidney cells. The REACT injection is an investigational therapy that is a mixture of kidney cells prepared from the participant’s own kidney tissue. Its patented technology includes multiple breakthroughs in the manufacturing and medical delivery of cellular therapy products. The company is conducting a global Phase 3 development program and multiple Phase 2 clinical trials for REACT in subjects with moderate to severe diabetic kidney disease.

Company Info

PROKIDNEY CORP

2000 Frontis Plaza Blvd., Suite 250

Winston-Salem NORTH CAROLINA

P: 13369997028

Employees: 87

Website: https://prokidney.com/

PROK News

News Image19 days ago - InvestorPlacePROK Stock Earnings: ProKidney Reported Results for Q4 2023

ProKidney just reported results for the fourth quarter of 2023.

News Image19 days ago - BusinessInsiderPROK Stock Earnings: ProKidney Reported Results for Q4 2023

InvestorPlace - Stock Market News, Stock Advice & Trading Tips ProKidney (NASDAQ:PROK) just reported results for the fourth quarter of 2023.Pr...

News Imagea month ago - ProKidneyProKidney Announces the Closing of $140 Million Public Offering of Class A Ordinary Shares and Concurrent Registered Direct Offering, Including Exercise of Underwriters’ Option
News Imagea month ago - ProKidneyProKidney Announces Pricing of its Upsized $130 Million Public Offering of Class A Ordinary Shares and Concurrent Registered Direct Offering
News Imagea month ago - ProKidneyProKidney Announces Pricing of its Upsized $130 Million Public Offering of Class A Ordinary Shares and Concurrent Registered Direct Offering

WINSTON-SALEM, N.C., June 11, 2024 (GLOBE NEWSWIRE) -- ProKidney Corp. (Nasdaq: PROK) (“ProKidney” or the “Company”), a leading late clinical-stage...

News Imagea month ago - InvestorPlaceToday’s Biggest Pre-Market Stock Movers: 10 Top Gainers and Losers on Tuesday

It's time to start the day with a breakdown of the biggest pre-market stock movers worth checking out on Tuesday morning!

PROK Twits

Here you can normally see the latest stock twits on PROK, but your cookie settings prevent this from loading. You can edit your cookie settings in our cookie consent dialog.

Example Twits:

Twits example